TRPM3 promotes autophagy through the calcium/calmodulin-dependent kinase kinase 2 (CAMKK2)/AMPK/ULK1 pathway, providing a potential target for ccRCC therapy (80). The gene discussed is TRPM3; the disease is nonpapillary renal cell carcinoma.